GRTX (OTC)
GALERA THERAPEUTICS INC
$0.021200
-0.000800 (-3.64%)
Prev close: $0.022000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- John Mel Sorensen
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $1.76M
- Employees
- 3
- P/E (TTM)
- -0.17
- P/B (TTM)
- -0.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2023 (Q3)
|
$-0.28 | $-0.41 | +0.1253 | +30.92% |
|
Jun 2023 (Q2)
|
$-0.48 | $-0.39 | -0.0941 | -24.38% |
|
Mar 2023 (Q1)
|
$-0.50 | $-0.39 | -0.1101 | -28.24% |
|
Dec 2022 (Q4)
|
$-0.58 | $-0.55 | -0.0321 | -5.86% |
Financial Statements
| Research and Development | $235.00K |
| Operating Income/Loss | -$10.00M |
| Income/Loss From Continuing Operations After Tax | -$8.99M |
| Income/Loss From Continuing Operations Before Tax | -$8.99M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Interest Expense, Operating | $0.00 |
| Net Income/Loss | -$8.99M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$8.99M |
| Net Income/Loss Available To Common Stockholders, Basic | -$6.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$2.45M |
| Preferred Stock Dividends And Other Adjustments | -$2.45M |
| Basic Earnings Per Share | -$0.10 |
| Diluted Earnings Per Share | -$0.10 |
| Basic Average Shares | 98,744,475 |
| Diluted Average Shares | 98,744,475 |
| Assets | $5.00M |
| Current Assets | $4.90M |
| Noncurrent Assets | $101.00K |
| Liabilities | $151.65M |
| Current Liabilities | $598.00K |
| Accounts Payable | $434.00K |
| Other Current Liabilities | $164.00K |
| Noncurrent Liabilities | $151.05M |
| Equity | -$149.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$149.22M |
| Liabilities And Equity | $5.00M |
| Net Cash Flow From Operating Activities | -$6.79M |
| Net Cash Flow From Operating Activities, Continuing | -$6.79M |
| Net Cash Flow From Investing Activities | $3.77M |
| Net Cash Flow From Investing Activities, Continuing | $3.77M |
| Net Cash Flow From Financing Activities | -$6.94M |
| Net Cash Flow From Financing Activities, Continuing | -$6.94M |
| Net Cash Flow | -$9.97M |
| Net Cash Flow, Continuing | -$9.97M |
| Comprehensive Income/Loss | -$8.99M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$8.99M |
| Other Comprehensive Income/Loss | $0.00 |